Beyond Cardiac Remote Monitoring

Founded as a remote monitoring company, PaceMate™ recognized the need for a robust platform to aggregate, store, and report data for cardiac implantable electronic device (CIED) encounters, remote and in-clinic, from all major vendors. PaceMate™LIVE, the best-available, cloud-native, vendor-neutral platform, utilizes 2-way electronic health record (EHR) integration to create clinical and operational efficiencies while promoting patient safety, quality, and clinician satisfaction.

Today, customers recognize the value that the PaceMate™LIVE platform brings to patients and their practice, either as a stand-alone software product or in conjunction with PaceMate™’s on-demand service offerings. However, the advantages of PaceMate™ go far beyond its original design to support transactional device encounters. PaceMate™ is transforming the way practices care for patients while also helping clinics to inform research investigations and population health initiatives.

Unprecedented Data Capabilities

A vast amount of structured data is collected by EHRs and via PaceMate™LIVE. PaceMate is the only software that stores every datapoint for full-scale search capabilities and retrospective analysis of patient data sets. Coupled with PaceMate™’s ability to pull any application programming interface (API)-supported datapoint from the EHR, the research possibilities are endless.

When discrete EHR data and discrete device data are combined, any datapoint or combination of datapoints from these sources can be studied. This level of interoperability is only achieved through PaceMate™’s membership in the marketplace of the major EHRs. Since its inception, PaceMate™ has invested heavily in building strong working relationships with major EHR vendors. Currently, PaceMate™ is listed in Epic’s App Orchard, the athenahealth Marketplace, and most recently, in the Cerner Open Developer Experience (CODE) program. These memberships are the only way to gain access to the powerful exchange of data via Fast Health Interoperability Resources (FHIR^®) APIs.

PaceMate™’s true, 2-way exchange of health information via FHIR APIs grants access to EHR data beyond patient demographics. EHR discrete data is pulled into PaceMate™LIVE immediately upon every device encounter—including ICD-10 diagnosis codes, active medications with doses and prescription and refill dates, care team details, and hospitalization encounter information.

Query-ready Data Source

PaceMate™ also integrates with multiple strategic partners in the ambulatory and consumer-driven cardiac monitoring arenas. Ambulatory cardiac monitoring devices contribute discrete data accessible via PaceMate™LIVE, including ECG interval measurements and arrhythmia occurrence—with frequency, rate, and duration data.

Because PaceMate™ pulls in data from CIEDs, ambulatory devices, and wearable devices, our query scope extends far beyond device model and serial numbers, dates of implant and encounters, and high-level patient demographics. PaceMate™ can build any query with customized parameters to answer a researcher’s scientific questions. Full-scale search capabilities within our research-grade data support retrospective and prospective analyses and are conveniently accessed on the PaceMate™LIVE dashboard with role-based access.

Supporting Recent Research

Numerous studies have been published examining arrhythmia burden in CIED patients. One recent study by O’Shea et al¹ utilized PaceMate™LIVE data to examine the association of device-detected atrial fibrillation incidence with COVID-19 infection rates in specific geographies. PaceMate™LIVE data is also being used by the University of North Carolina² in a follow-up study to examine the impact of exposure to the 2020 presidential campaign on a CIED patient population.

PaceMate™ is the only cardiac monitoring company capable of generating data insights that are suitable for addressing multiple areas of interest, including CIED and lead programming and performance, CIED therapies, arrhythmias, disease management related to atrial fibrillation, heart failure, ventricular arrhythmias and COVID-19 impact, as well as manufacturer-specific programming and performance. Studies to examine quality, patient safety, efficiency, and healthcare utilization can be informed with discrete EHR data and discrete data from implantable and wearable devices in PaceMate™LIVE.

PaceMate™. The best available cardiac remote monitoring software with unprecedented research-grade data capabilities.

SCHEDULE A DEMO

PaceMate.com | 1.844.4VIPMED | We never miss a beat.™

Can your software do that?

This article is published with support from PaceMate™.

References

1. O’Shea CJ, Middeldorp ME, Thomas G, et al. Atrial fibrillation burden during the coronavirus disease 2019 pandemic. EP Europace. 2021;23(9):1493-1501. https://doi.org/10.1093/europace/euab099
2. Rosman L, Salmoirago-Blotcher E, Mahmood R, et al. Arrhythmia risk during the 2016 US presidential election: the cost of stressful politics. J Am Heart Assoc. 2021;10(11):e020559. https://doi.org/10.1161/JAHA.120.020559

Recommended Reading:

Journal Articles

O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote monitoring of implantable loop recorders: false-positive alert episode burden. Circ Arrhythm Electrophysiol. 2021;14(11):e009635. https://doi.org/10.1161/CIRCEP.121.009635

O’Shea CJ, Thomas G, Middeldorp ME, et al. Ventricular arrhythmia burden during the coronavirus disease 2019 (COVID-19) pandemic. Eur Heart J. 2021;42(5):520-528. https://doi.org/10.1093/eurheartj/ehaa893

O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote monitoring alert burden: an analysis of transmission in >26,000 patients. JACC: Clinical Electrophysiol. 2021;7(2):226-234. https://www.ahajournals.org/doi/10.1161/CIRCEP.121.009635

Abstracts

Heath K, O’Shea C, Thomas G, et al. B-PO02-008 Impact of intensive follow-up of cardiac implantable electronic devices via remote monitoring: a pilot study. Heart Rhythm. 2021;18(suppl 8):S98-S99. https://doi.org/10.1016/j.hrthm.2021.06.265

Noubiap JJ, Thomas G, Harper C, et al. B-PO02-051 Atrial arrhythmia detection using insertable cardiac monitors in patients with cryptogenic stroke: a real-world cohort study. Heart Rhythm. 2021;18(suppl 8):S116. https://doi.org/10.1016/j.hrthm.2021.06.307

O'Shea C, Middeldorp ME, Brooks AG, et al. B-PO02-052 Device detected atrial fibrillation: anticoagulation rates in patients undergoing intensive remote monitoring. Heart Rhythm. 2021;18(suppl 8):S117. https://doi.org/10.1016/j.hrthm.2021.06.308